中山醫學大學機構典藏 CSMUIR:Item 310902500/24403
English  |  正體中文  |  简体中文  |  全文笔数/总笔数 : 17938/22957 (78%)
造访人次 : 7394005      在线人数 : 191
RC Version 7.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜寻范围 查询小技巧：
  • 您可在西文检索词汇前后加上"双引号"，以获取较精准的检索结果
  • 若欲以作者姓名搜寻，建议至进阶搜寻限定作者字段，可获得较完整数据
    •  进阶搜寻


    jsp.display-item.identifier=請使用永久網址來引用或連結此文件: https://ir.csmu.edu.tw:8080/ir/handle/310902500/24403


    题名: The therapeutic benefits of combined sorafenib and transarterial chemoembolization for advanced hepatocellular carcinoma
    作者: Lee, SW;Lee, TY;Peng, YC;Yang, SS;Yeh, HZ;Chang, CS
    关键词: hepatocellular carcinoma;sorafenib;transarterial chemoembolization
    日期: 2020
    上传时间: 2022-08-09T08:01:43Z (UTC)
    出版者: WILEY
    ISSN: 1751-2972
    摘要: Objective Systemic therapy, such as sorafenib, has been used clinically to treat patients with advanced stage or Barcelona Clinic Liver Cancer staging system (BCLC) stage C hepatocellular carcinoma (HCC). The aim of the study was to evaluate the therapeutic benefit of combined sorafenib and transarterial chemoembolization (TACE) in this group of patients. Methods Data on patients with HCC at BCLC stage C from August 2012 to September 2017 were collected. Patients who were given sorafenib alone were classified as the monotherapy group and those taking sorafenib and TACE were classed as the combined therapy group. Results A total of 118 patients were enrolled. There were 65 and 53 patients in the monotherapy and the combined therapy group, respectively. The groups' general characteristics were similar. Compared with the monotherapy group the combined therapy group experienced prolonged time-to-progression (TTP) (mean 6.42 mo vs 3.63 mo, P = 0.003) and overall survival (OS) (mean 11.21 mo vs 5.98 mo, P = 0.001). A subgroup analysis found that patients with macroscopic vascular invasion (MVI) also had prolonged TTP and OS in the combined therapy group than the monotherapy group (mean TTP, 7.93 mo vs 3.43 mo, P = 0.007; mean OS, 13.41 mo vs 5.50 mo, P = 0.001), however, these significant differences did not exist for those with extrahepatic spread (EHS). Conclusion Combined sorafenib and TACE therapy has significant better outcomes than sorafenib alone in patients with stage C HCC, particularly those with MVI.
    URI: http://dx.doi.org/10.1111/1751-2980.12866
    https://www.webofscience.com/wos/woscc/full-record/WOS:000537512000001
    https://ir.csmu.edu.tw:8080/handle/310902500/24403
    關聯: JOURNAL OF DIGESTIVE DISEASES ,2020 ,v21 ,issue 5 ,p287-292
    显示于类别:[中山醫學大學研究成果] 期刊論文

    文件中的档案:

    档案 描述 大小格式浏览次数
    index.html0KbHTML202检视/开启


    SFX Query

    在CSMUIR中所有的数据项都受到原著作权保护.

    TAIR相关文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回馈